In this video update, HCC CONNECT expert Prof. Matthias Pinter reviews recent real-world data (RWD) discussed in advanced HCC.

He discusses real-world efficacy and safety of systemic therapies, treatment patterns in real-world clinical practice, and RWD on systemic therapy in patient populations excluded from Phase 3 RCT (Child-Pugh class B and with a history of liver transplantation).

 

Clinical takeaways:

  • Although RWD cannot substitute controlled randomised clinical trials, RWD addresses questions not sufficiently answered by clinical trial data
  • RWD can provide insights into the performance and outcomes of new anticancer therapies in routine clinical practice, information on patients underrepresented in clinical trials and captures less common and delayed adverse events

Dr Matthias Pinter works at the Medical University of Vienna in Austria where he also received both his MD and PhD. He is board-certified for Internal Medicine and Gastroenterology and Hepatology. Since 2017, he has led the hepatocellular carcinoma programme and research group at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. His main research interests include the systemic treatment of liver cancer, particularly the identification of prognostic markers and scores that may help to identify patients most likely to benefit from specific therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories oncology, gastroenterology and hepatology, and radiology.

Assoc. Prof. Matthias Pinter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Ipsen, Eisai, Lilly, MSD and Roche.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

GI-oncology-GI-CONNECT-10-years-thumbnail-GI2403 Video
Oncology 
Celebrating the 10th anniversary of GI CONNECT

10 years of independent medical education in GI oncology

Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest
  • clock 2 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer